Eli Lilly reported new type 2 diabetes data for two obesity candidates: the triple agonist retatrutide produced up to 18.8% weight loss at 18 months when analyzed under the regulatory-standard treatment regimen estimand, down from the 20.8% figure derived from the completer-based efficacy analysis. A separate Phase 2 combination of the amylin agonist eloralintide with tirzepatide reached 23.3% weight loss at roughly 11 months, with HbA1c falling 2.9%. The divergence between the two estimands illustrates how analytic conventions shape the interpretation of efficacy as much as the pharmacology does.
Key Points
- Retatrutide: 18.8% weight loss under regulatory estimand, 20.8% among completers
- Eloralintide plus tirzepatide reached 23.3% loss, HbA1c down 2.9%
- Dysesthesia affected 7% at retatrutide's highest dose versus 1% placebo
Longevity Analysis
Sixty percent of participants exited the obesity category and 23% fell below the overweight threshold, shifts that alter glycemic control, vascular load, and inflammatory burden simultaneously rather than in isolation. The estimand distinction matters for anyone interpreting these results clinically: completer analyses describe the drug's ceiling, while intention-to-treat figures describe what happens across real adherence patterns, including the 8-12% who discontinued for side effects. Pharmacological weight reduction of this magnitude removes a significant metabolic interference, but the durability of benefit still depends on what sustains lean mass, movement capacity, and nutritional adequacy once the weight is gone.
Original published by Longevity.Technology, by Kyle Umipig.